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Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH):
A Case Presentation and Overview of Documented Cases
Samer Bolis, DO, Yehia Mishriki, MD, Jessica Boehmler, MD
Lehigh Valley Health Network, Allentown, PA

Introduction
•	Pulmonary neuroendocrine cells (PNECs) span
the entire respiratory tract, synthesizing amines,
peptides, and cytokines (serotonin, gastrin,
chromogranin A, and bombesin). They are known to
undergo reactive hyperplasia in response to chronic
injury.
•	The World Health Organization (WHO) recognized
diffuse idiopathic pulmonary neuroendocrine cell
hyperplasia (DIPNECH) as a primary, pre-invasive
form of PNEC proliferation with a spectrum ranging
from tumorlet to carcinoid tumor formation within
the terminal and respiratory bronchioles (1999).
•	DIPNECH can lead to varying degrees of obstructive
ventilatory defects secondary to fibrosis and
proliferation of PNECs beyond the basement
membrane.
•	High resolution CT (HRCT) screening has led to the
increasing recognition and understanding of the
disease, accounting for 130 cases described in
current literature.

Discussion
Review of the literature revealed that our patient presented with typical features of
DIPNECH (Table 1). The majority of patients are symptomatic and are misdiagnosed
for years.

Fig. 1a

Figure 1a: HRCT - Right upper lobe pulmonary nodules.

Fig. 1b

Figure 1b: HRCT – Expiratory image demonstrating air
trapping (Post right upper wedge resection).

•	Transbronchial biopsy and lavage have shown a low yield while PFT testing
reveals an obstructive pattern in most symptomatic patients.
•	HRCT scans should be obtained with the addition of expiratory imaging to aid
in recognition of the mosaic pattern of air trapping suggestive of constrictive
obliterative bronchiolitis.
•	The current gold standard of diagnosis remains a surgical lung biopsy with
histopathologic confirmation.
•	Typical disease course is indolent and non-progressive with a small
percentage of cases experiencing clinical deterioration. The majority of
patients have a favorable long term survival with observation alone.
•	While there is no known definitive treatment for DIPNECH, limited data
reports improvement with systemic/inhaled steroids. Somatostatin analogs
such as Octreotide have inconsistently shown stabilization of disease
progression.
•	The use of cytotoxic agents is not recommended and may be detrimental.
Elevated serum biomarkers and ipsilateral lymph nodal metastasis have
been reported but did not predict a poorer outcome.

Case

Table 1. Features of DIPNECH (N=109)
Sex

A 70-year-old Caucasian female life-long non-smoker
with a chronic cough of 25 year duration had been
unsuccessfully treated for presumed allergic rhinitis,
postnasal drip, and cough variant asthma. Bronchoscopy
was unrevealing while a HRCT scan of the chest
discovered two pulmonary nodules with moderate air
trapping on expiratory imaging (Figure 1).
The patient underwent wedge resection with pathology
revealing carcinoids with tumorlets and PNEC hyperplasia
(Figure 2). These tumors were hormonally inactive and
a full workup disclosed no metastases. Her current
treatment consists of cough suppression with an opiate.

Age
Ethnicity
Tobacco History
Symptomatic
Symptom Type
Duration
PFT
HRCT Findings
Biopsy Results
Prognosis (2-5yr)

Female predominance of 92%
34 - 78 years (mean 57; median 62)
Caucasian predominance suggested
33% active/former smokers
55% - 89%
Cough (71%), dyspnea (63%), wheezing (25%)
6 months to > 2 decades
Obstructive (63-86%), restrictive (13%), mixed (17%), nurmal (17%)
96% air trapping, 62% one or more pulmonary nodules, 29% ground glass, 21% bronchiectasis
88% tumorlets, 40% carcinoid tumors, 44% constrictive bronchiolitis
41-45% stable course, 26-32% decline on PFT, 35% improved with treatment (inhaled steroids 67%, oral steroids 46%,
octreotide 17%)
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